Indeloxazine is a neuroleptic, originally developed and marketed in Japan. It is indicated to allay autonomic hyperactivity following cerebral infarction, cerebral haemorrhage or atherosclerosis. It was found to be a weak inhibitor of both type A and type B monoamine oxidases. Indeloxazine-induced facilitation of acetylcholine release in frontal cortex is mediated by endogenous 5-HT and involves at least in part cortical 5-HT4 receptors. As a potential teratogen, Indeloxazine must not be consumed or handled by pregnant or nursing women, or by women who might become pregnant. It was removed from the market reportedly for lack of effectiveness.

Dilazep is a coronary and cerebral vasodilator as an adenosine reuptake inhibitor. Dilazep is an inhibitor of platelet aggregation and of membrane transport of nucleosides. Dilazep is also known to have a vasodilating effect on renal vessels and is often used in patients with ischaemic heart disease, cerebral ischemia or renal dysfunction to improve tissue circulation.

Bifemelane is a psychotropic drug, was found to inhibit monoamine oxidase (MAO). It inhibited type A MAO (MAO-A) competitively and type B (MAO-B) noncompetitively and it was a more potent inhibitor of MAO-A than of MAO-B. Bifemelane is an antidepressant and cerebral activator that is used in Japan for the treatment of cerebral infarction patients with depressive symptoms, and in the treatment of senile dementia as well. It also appears to be useful in the treatment of glaucoma.

Dilazep is a coronary and cerebral vasodilator as an adenosine reuptake inhibitor. Dilazep is an inhibitor of platelet aggregation and of membrane transport of nucleosides. Dilazep is also known to have a vasodilating effect on renal vessels and is often used in patients with ischaemic heart disease, cerebral ischemia or renal dysfunction to improve tissue circulation.